Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25001645 | 0.90 | HRH3 (0.38) | HRH3SLC6A4SIGMAR1 | |
| SCHEMBL24802112 | 0.87 | HRH3 (0.45) | HRH3SLC6A4SIGMAR1CYP3A4CYP2C9 | |
| SCHEMBL23205185 | 0.83 | HRH3 (0.41) | HRH3 | |
| SCHEMBL25960101 | 0.82 | ALDH1A1 (0.35) | HRH3 | |
| SCHEMBL10025501 | 0.81 | HRH3 (0.55) | HRH3CYP3A4CYP2C9 | |
| SCHEMBL25955435 | 0.81 | GNAI3 (0.40) | SIGMAR1CYP2C9TMEM97 | |
| SCHEMBL24802114 | 0.80 | TLR7 (0.43) | SIGMAR1TMEM97 | |
| SCHEMBL25955433 | 0.80 | GNAO1 (0.46) | — | |
| SCHEMBL26047964 | 0.79 | GNAO1 (0.49) | — | |
| SCHEMBL25959918 | 0.78 | SMN1; SMN2 (0.43) | SLC6A4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | HRH3 3390/4885SLC6A4 4244/4885SIGMAR1 3592/4885 |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | CRBN, CDR2, CRKL | HRH3 3647/4885SLC6A4 4340/4885SIGMAR1 4156/4885 |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | EGFR, ERBB2, CBL | HRH3 3471/4885SLC6A4 4526/4885SIGMAR1 3843/4885 |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | HRH3 3390/4885SLC6A4 4244/4885SIGMAR1 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.